Announcement 29.07.2013 Reference is made to announcement no. 21-13 of 17 July 2013 in which NeuroSearch A/S (NEUR) announced that the company is being prosecuted by the Danish Public Prosecutor for Special Economic and International Crimes (SEIC) for alleged qualified share price manipulation. In the indictment, which was released today, SEIC states that prosecution is initiated against NeuroSearch as a legal entity and the CEO employed in company at the time of the alleged share price manipulation. Thus, neither the present Management nor members of the present and former Board of Directors have been prosecuted. For further information, NeuroSearch refers to the indictment and the Danish Public Prosecutor for Special Economic and International Crimes. On the present basis, NeuroSearch denies the charges and fully collaborates with the authorities to resolve the matter. René Schneider CEO Contact person René Schneider, CEO, telephone: +45 2911 2097 About NeuroSearch NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I. All drug candidates exert their effect in the central nervous system.
NeuroSearch advises that the indictment concerning alleged
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
PotlatchDeltic Reveals Tax Implications for 2024 Shareholder Dividends
PotlatchDeltic Reveals Dividend Tax Treatment for 2024 PotlatchDeltic Corporation (Nasdaq: PCH) is stepping into the spotlight by announcing the tax treatment for its anticipated dividend distributions throughout the year. As a prominent player in the real estate investment sector, this announcement brings clarity to investors regarding how dividends will be categorized...
Continue Reading
Beyond Air Secures $3.25 Million from Warrant Exercises
Beyond Air's Strategic Moves to Boost Capital Beyond Air, Inc. (NASDAQ: XAIR), a leading medical device and biopharmaceutical company, is making waves in the financial realm. Focused on the innovative use of nitric oxide (NO) to enhance patient care, Beyond Air has announced the immediate exercise of certain outstanding warrants, aiming to generate approximately $3.25...
Continue Reading
Dr. Sven Kili Joins Saisei Ventures as New Partner
Saisei Ventures Welcomes Dr. Sven Kili as Partner Saisei Ventures, a prominent investment firm focused on the advancement of biotechnology and therapeutic innovations, has announced an exciting new chapter in its journey. Dr. Sven Kili, MD, has been appointed as a partner, marking a significant addition to the team's leadership. Dr. Kili, who played an advisory role since...
Continue Reading
MangoRx Unveils Innovative Tirzepatide Tablet for Weight Loss
Mangoceuticals, Inc. (NASDAQ: MGRX) launched its new oral Tirzepatide tablet, TRIM, back in 2024 at a steep price of $399 per month. Traders noticed this shift towards a convenient alternative to traditional injectables and were already debating the long-term implications on sales and market share. TRIM's Role: A Game Changer for Weight Management? Tirzepatide has made...
Continue Reading
Mama’s Creations Q2 FY2025 Earnings Call Announcement
Mama’s Creations to Host Earnings Call for Second Quarter FY2025 Mama’s Creations, Inc. (NASDAQ: MAMA), a leading national marketer and manufacturer of fresh deli prepared foods, is preparing to announce its financial results for the fiscal second quarter, which ended on July 31. The earnings call is scheduled to take place after the market closes on September 10....
Continue Reading